Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide +/- Fluzoparib in mCRPC
NCT02747342Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Sep 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rezvilutamide in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Recommended Phase 2 Dose at 24 months. Started Sep 2016; status: completed.
02
Drugs
rezvilutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02747342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747342.